Healthcare Services Industry Overview

IVF Services Market Definition

The IVF services market consists of sales of in vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide IVF services which is one of the more widely known types of assisted reproductive technology (ART) used to address infertility. IVF is a process of fertilization where an egg is combined with sperm outside the body, in vitro ("in glass"). In IVF treatment procedure, matured eggs are collected or retrieved from woman’s ovaries and then mixed with a partner or a donor’s sperm cells in a lab - called insemination. The combined eggs and sperm are stored in a petri dish (in vitro). The cultured cells will develop as embryos in fertilized eggs and then the fertilized egg (embryo) or eggs (embryos) are transferred to a uterus. The procedure normally takes about three weeks and in some cases the process can take longer depending on the factors such as patients’ age and the cause of infertility.

Telehealth Market Definition

The telehealth market consists of sales of telehealth services, software and hardware by entities (organizations, sole traders and partnerships) that are engaged in providing clinical and non-clinical healthcare services and solutions digitally, for the smooth functioning of healthcare services. Telehealth is the use of electronic data and telecommunications technology to promote long-distance medical healthcare services, patient and professional health education, public health, and health management. Technologies comprise streaming media, teleconferencing, web, store-and-forward imaging, terrestrial and wireless communications. Telehealth includes healthcare services and nonclinical health education and public health programs.

The mobile imaging services market consists of sales of mobile imaging services by entities (organizations, sole traders, and partnerships) that are engaged in providing imaging services such as computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging services directly to medical facilities, homes and businesses. Through mobile equipment, it is possible to deliver imaging services patients having location or cost constraints. Mobile imaging services provide X-rays, EKGs, and ultrasounds delivered to medical facilities, families, and businesses. It is usually less expensive and quicker than third-party options, and it can help overwhelmed in-house imaging departments. The main types of products in the mobile imaging services market include X-ray, ultrasound, CT, MRI, mammography, bone densitometry, and others. The X-ray tube (an evacuated tube with a cathode and anode) generates X-rays when a flow of electrons propelled to high speeds by a high voltage intersects with the tube target anode. Mobile X-ray is done through mobile digital radiology (DR) systems have built-in or tethered flat panel sensors that transform X-rays to visible light using a scintillator material. Ultrasound is a diagnostic imaging test that uses sound waves through small and light devices to create a picture known as a sonogram of the body organs tissues, and other structures inside the body. A computerized tomography (CT) scan is an imaging technique to get detailed images of the body noninvasively. Magnetic resonance imaging (MRI) is an imaging technique to get produces three dimensional detailed anatomical images using magnetic resonance instead of radiation. Mammography is an imaging technique involving usage of low-energy X-rays to examine the human breast in order for early detection of breast cancer. Bone densitometry is an imaging technique to measure the density of bones. Mobile imaging services are implemented in different verticals such as hospitals and private clinics, home healthcare providers, rehabilitation centers, geriatric care and hospice agencies, sports organizations, and others. The global mobile imaging services market is expected to grow from $14.36 billion in 2020 to $15.84 billion in 2021 at a compound annual growth rate (CAGR) of 10.29%. The growth in the mobile imaging services market is mainly due to the increasing patient pool and awareness towards early diagnosis of diseases. The market is expected to reach $18.97 billion in 2025 at a CAGR of 4.61%. The rising prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular diseases is expected to propel the growth of the mobile imaging services market in the forecast period. Chronic disease is a long-term health problem for which there is no cure. These diseases last for more than 1 year and require continuous medical attention or would otherwise limit activities of daily living. These diseases generally cannot be prevented by vaccines or cured by medication. Globally, chronic illnesses are the major cause of death and disability, disease rates from these conditions are increasingly spreading through all regions and affecting people of all socioeconomic backgrounds. Mobile imaging services help care providers perform many kinds of vital screenings by using various imaging technologies such as X-Ray, EKG, and ultrasound. For instance, according to the United Nations, the proportion of total global deaths due to chronic diseases is expected to increase to 70% by 2030. Therefore, the rising prevalence of chronic diseases drives the growth of the mobile imaging services market. Strategic collaborations and acquisitions are a key trend gaining popularity in the mobile imaging services market. Major players in the mobile imaging services market are focusing on collaborations and acquisitions to build innovations and remain competitive. For instance, in July 2020 GE Healthcare collaborated with University Hospitals (UH) Cleveland Medical Center to develop a new AI-based mobile X-Ray system that includes Critical Care Suite, the first on-device artificial intelligence (AI) platform for detecting and prioritizing collapsed lungs. Moreover, Koninklijke Philips acquired Carestream Health Healthcare Information Systems (HCIS) business in August 2019, solidifying the commitment of the company to provide industry-leading medical imaging and healthcare IT solutions. In August 2019, Koninklijke Philips N.V., a Netherlands–based health technology company acquired Carestream Health Healthcare Information Systems for an undisclosed amount. The acquisition would enable Koninklijke Philips N.V. to strengthen the commitment to supply industry-leading medical imaging and healthcare IT solutions. Carestream Health is a USA-based company that provides X-Ray imaging systems for medical, non-destructive testing, and precision contract coating services. Major players in the mobile imaging services market are Accurate Imaging Inc., Alliance HealthCare Services Inc., Axiom Mobile Imaging, Carestream Health, Center for Diagnostic Imaging Inc., Cobalt Health, DMS Health Technologies Inc., Front Range Mobile Imaging Inc., Imaging On Site Inc., InHealth Group Limited, Interim Diagnostic Imaging LLC, Jacksonville Mobile Imaging Services Inc., Nuffield Health, Digirad Corporation, and TridentUSA Health Services. North America was the largest region in the mobile imaging services market in 2020. The regions covered in the mobile imaging services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the mobile imaging services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global mobile imaging services market is segmented - 1) By Product Type: X-Ray, Ultrasound, CT, MRI, Mammography, Bone Densitometry 2) By End User: Hospitals And Private Clinics, Home Healthcare Providers, Rehabilitation Centers, Geriatric Care And Hospice Agencies, Sports Organizations, Others

The mycoplasma testing market consists of sales of mycoplasma testing services and related products by entities (organizations, sole traders, and partnerships) that provide mycoplasma testing to detect mycoplasma pneumoniae, which causes mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory fluids. It can cause epidemics. Mycoplasma testing includes a group of tests that measures antibodies in the blood produced in response to a mycoplasma infection and detects the microbe directly through detecting or culturing its genetic material (DNA) in a body sample. The main types of mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. Polymerase chain reaction (PCR) detects mycoplasma species using primers specific for mycoplasma DNA, usually mycoplasma 16S rRNA genes. Enzyme-linked immunosorbent assay (ELISA) detects the presence of mycoplasma using either antibodies, or labeled probes for the mycoplasma 16S rRNA genes. Enzymatic methods use a sample of the suspected cell culture which converts ADP to ATP using mycoplasmal enzymes. Deoxyribonucleic acid (DNA) staining detects the mycoplasma strain M. hyorhinis by growing a sample of suspected cell cultures with Vero cells, and staining the cells for DNA using a fluorescent dye. The different products in mycoplasma testing include instruments, assay, kits, and reagents. Mycoplasma testing is applied in cell line testing, virus testing, and end- of- production cell testing and is used by pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organizations, academic research institutes. The global mycoplasma testing market is expected to grow from $0.64 billion in 2020 to $0.72 billion in 2021 at a compound annual growth rate (CAGR) of 12.4%. The growth is mainly due to a growing demand for these type of tests owing to an increase in spread of mycoplasma pneumonia. The mycoplasma testing market is expected to reach $1.14 billion in 2025 at a CAGR of 12.38%. The prevalence of mycoplasma pneumonia co-infection among patients with COVID-19 is expected to boost the market for mycoplasma testing in the forecast period. The presence of co-infection of M. pneumonia increases the need to test patients with COVID-19, increasing demand for routine diagnostic tests for respiratory pathogens like M. pneumonia. The coinfections in COVID-19 cases has a significant probability of them being caused by Mycoplasma pneuminiae. For instance, according to a 2020 study published in the Archives of Medical Laboratory Sciences, the co-infection due to M. pneumonia varied between 1 and 40.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17%. The lack of skilled/trained molecular biologists is expected to restrain the growth of the market in the forecast period. Mycoplasma testing requires specialized skillsets relating to life sciences, pharmaceuticals, electronics and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. Lack of trained manpower capable of performing the molecular biology experiments and interpreting the results is a major limitation in the testing and confinement of COVID-19 in developing countries. For the few laboratory experts present in these countries, priority is given to other medical emergencies such as heart attacks and road accidents. This shortage of skilled labor is expected to be a significant deterrent to the growth of the market during the forecast period. Major players operating in the market are undertaking various strategic investments such as the launch of innovative products, research and development advancements, and technological innovations, which are gaining significant popularity in the mycoplasma testing market. Companies are introducing new innovative products to meet the requirements of end-users and expand the consumer base to survive in the competitive business environment. For instance, in July 2020, bioMérieux, a France-based biotechnology company introduced Bio Fire Mycoplasma, an advanced test used for bio-therapeutics including hormones, antibodies, gene, and cell therapies for mycoplasma detection in pharmaceutical products. In another instance, in March 2019, Lonza, a Switzerland-based chemicals and biotechnology company, launched Lucetta 2 Luminometer to increase the accuracy and speed of mycoplasma detection in cell culture experiments. The luminometer is a single-tube system intended to accelerate and simplify mycoplasma detection in cell cultures. In January 2020, Charles River Laboratories International, Inc., a USA-based company specializing in a variety of preclinical and clinical laboratory services for the biotechnology, pharmaceuticals, and medical devices industry acquired HemaCare Corporation for approximately $380 million in cash. With the acquisition, Charles River Laboratories International, Inc. expands the scientific capabilities of the company in the high-growth cell therapy sector and HemaCare cellular products improve Charles River Laboratories ability to offer a comprehensive cell therapy solution, including mycoplasma detection. HemaCare Corporation is a USA-based company engaged in the production of human-derived biological products and services for cellular therapy development, drug discovery, and biomedical research. Major players in the mycoplasma testing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International Inc., Bionique Testing Laboratories Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Agilent Technologies, Abbott, Roche Diagnostics, Boston Scientific Corporation, Clongen Laboratories LLC, Creative Bioarray, Nelson Laboratories Fairfield Inc., Norgen Biotek Corporation, Biotools B & M Labs S.A, GenBio, GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc., AngioDynamics, AtriCure Inc., CONMED Corporation, Olympus Corporation, Smith & Nephew, and Advanced Cardiac Therapeutics. North America was the largest region in the mycoplasma testing market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mycoplasma testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global mycoplasma testing market is segmented - 1) By Product: Instruments, Assay, Kits, and Reagents 2) By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies 3) By Application: Cell Line Testing, Virus Testing, End-of-Production Cell Testing 4) By End User: Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organizations, Academic Research Institutes

The soft tissue repair market consists of sales of soft tissue repair by entities (organizations, sole traders, and partnerships) that manufacture soft tissue repair products. Soft tissue repair is defined as the replacement of wounded or damaged tissues with healthy tissues. The main types of soft tissue repair products include fixation devices, tissue patch or mesh, laparoscopic instruments. Fixation devices provide alignment and stabilization to the torn connective tissue. These include devices like cortical buttons and corresponding suture kits which helps enable the tension and the ability to attach tendon or tendon graft directly to the bone inside a pre-drilled socket. Tissue patch or mesh is a specialty biomaterial used for soft tissue repairs by supporting damaged tissues during the healing process. The laparoscopic instruments include various dissectors, graspers, scissors, electrodes, needle holders, and shaft and connection configurations for handling soft tissues during surgeries. The soft tissue repair is used in hernia repair, dural repair, skin repair, vaginal sling procedures, orthopedic repair, dental repair, breast reconstruction repair. These products are used by hospitals, clinics, research and academic institutes, others. The global soft tissue repair market is expected to grow from $8.78 billion in 2020 to $9.26 billion in 2021 at a compound annual growth rate (CAGR) of 5.5%. The growth is mainly due to the rising incidence of soft tissue injuries among the growing geriatric population. The soft tissue repair market is expected to reach $13.17 billion in 2025 at a CAGR of 9.2%. The increasing cases of sport-related injuries boosted the growth of the soft tissue repair market in the historic period. Sports injuries are injuries that occur when participating in sports or exercising. In sports, soft tissue injuries are the most frequent. Tissues that attach, sustain, or surround other body structures and organs are referred to as soft tissue. For instance, according to the British Journal of Sports Medicine, 12% of Olympic athletes were injured during the 2018 Winter Olympics. In 2018, more than 3.5 million children aged 14 and under were injured when engaging in sports or leisure activities. Therefore, the increasing prevalence of sport-related injuries drove the growth of the soft tissue repair market. The stringent regulatory standards for products like tissue mesh restrained the market growth in the historic period. The FDA requires manufacturers of these products to address safety concerns, through a rigorous premarket approval (PMA) pathway to demonstrate safety and effectiveness. The strong clinical requirements for surgical mesh and strict compliance to reduce risks could delay product approvals and thus restrain the market for soft tissue repair in the forecast period. Companies in the soft tissue market are investing in technological developments for increasing market share and providing innovative products to customers. Major companies operating in the soft tissue repair sector are focused on developing a technologically advanced solution for soft tissues. For instance, in April 2020, In2Bones, a USA-based designer, manufacturer, and distributor of medical devices for the treatment of disorders and injuries launched ClearGuard LE Endoscopic Soft Tissue Release System in the USA, which is used by orthopedic and podiatric specialists to treat a variety of foot problems. The ClearGuard LE Endoscopic Soft Tissue Release System gives orthopedic and podiatric specialists an easy-to-use, repeatable, and cost-effective system for high-volume lower extremity soft tissue surgeries such as plantar fascia, gastrocnemius, tarsal tunnel, and Morton's neuroma. In December 2020, Integra Lifesciences, a USA-based medical device company acquired ACell for $300 million. The acquisition is expected to expand Integra Lifesciences regenerative capabilities and is complementary to the existing tissue technologies portfolio of the company. ACell is a USA-based company that develops and manufactures unique extracellular matrix products to repair and remodel damaged tissues through remodeling. Major players in the soft tissue repair market are Organogenesis Inc., Stryker Corporation, Johnson & Johnson, Arthrex Inc, CryoLife Inc., Integra Lifesciences Corporation, Wright Medical Technology, Smith & Nephew plc, C.R. Bard Inc., Athersys Inc., Medtronic Plc, Zimmer Biomet Holdings Inc., Lifenet Health Inc., Isto Biologics, Covidien plc, Becton Dickinson and Company, LifeCell Corporation, Baxter Healthcare Corporation, and Boston Scientific Corporation. North America was the largest region in the soft tissue repair market in 2020. Asia Pacific region is predicted to record fastest growth over the forecast period. The regions covered in the soft tissue repair market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the soft tissue repair market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global soft tissue repair market is segmented - 1) By Product: Fixation Devices, Tissue Patch Or Mesh, Laparoscopic Instruments 2) By Application: Hernia Repair, Dural Repair, Skin Repair, Vaginal Sling Procedures, Orthopedic Repair, Dental Repair, Breast Reconstruction Repair 3) By End-User: Hospitals, Clinics, Research And Academic Institutes, Others

The cell therapy technologies market consists of sales of cell therapy technologies that are medicinal solutions used for developing and improving cell therapy, such as cell processing, cell banking, and point-of-care technologies. Cell therapy is a type of treatment used to inject active cells into the body of a patient for treating some disorders. This therapy seeks to treat diseases by altering certain sets of cells. In this technique, cells, which originate from the patient or a donor are modified outside the body and then injected into the patient. The main types of products in cell therapy technologies are consumables, equipment, systems & software and is applied on the different type of cells including t-cells, stem cells, and other cells. Stem cells are special human cells that can become almost any type of cell in the human body. This can range from brain cells to muscle cells and is also used to fix damaged tissues. T-cells are white blood cells and are critical to the immune system for responding against specific foreign substances or pathogens. The process involved in cell therapy technologies includes cell processing, cell preservation, distribution, and handling, process monitoring and quality control. Cell therapy technologies are used in various sectors including life science companies, research institutes. The global cell therapy technologies market is expected to grow from $2.36 billion in 2020 to $2.96 billion in 2021 at a compound annual growth rate (CAGR) of 25.4%. The growth is mainly due to an increase in investments in cell therapies and the growth in research and development for cell therapy. The cell therapy technologies market is expected to reach $5.57 billion in 2025 at a CAGR of 17.1%. Increasing investments by the government in cell-based research contributed to the growth of the global cell therapy technologies market. Governments are increasingly investing in research activities for developing therapies for diseases such as cancer, cardiovascular disease (CVD), and others. For instance, in November 2019, the Australian government released $150 million, over 10 years, for The Stem Cell Therapies Mission. The funding was obtained by Medical Research Future Fund (MRFF), to support Australian researchers to deliver new therapies. Moreover, in August 2019, Newcastle University spin-out Atelerix, pioneers in the storage and transport of cells at room temperature, were awarded a grant of £267,000 ($292,087) from Innovate UK, with collaborators Rexgenero and the cell and gene therapy catapult. Thus, the upsurge in government investments in cell-based research boosted the demand for the cell therapy technologies market in the historic period. High costs associated with cell therapy is expected to restrain the market in the forecast period. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. For example, cell therapies, especially gene-editing cell therapies such as CAR-T therapy highly expensive. The two first CAR T-cell therapies, Kymriah and Yescarta, have been given price tags of $475,000 and $373,000 respectively, in the USA, with similar pricing in Europe. Thus, the high cost of cell therapy is restraining the growth of the market. Strategic collaborations and partnerships between the industry players are gaining popularity in the cell therapy technologies market. Major companies are collaborating and partnering with other companies to developing new technologies in cell therapy areas for the treatment of a variety of diseases. For instance, in August 2020, IsoPlexis Corporation, USA-based collaborated with Lonza, a Switzerland-based chemicals and biotechnology company to enable the next generation of precision cell therapy manufacturing. In another instance, in July 2020, Hitachi, Ltd., a Japan-based provider of a broad range of solutions including automated cell culture technologies to pharmaceutical companies in the area of cell therapy and regenerative medicine industry collaborated with ThinkCyte, Inc., a Japan-based biotechnology company to focus on developing artificial intelligence (AI)-driven cell analysis and sorting system. In March 2020, Danaher Corporation, a USA-based company that designs, manufactures, and markets professional, medical, industrial, and commercial products, and services acquired General Electric (GE) biopharma business for $21.4 billion. The biopharma business was a part of the GE life sciences division that offered software and equipment used in biopharmaceutical research. The acquisition is expected to expand Danahe life sciences business. General Electric Company is an American company that operates in four industrial segments: aviation, power, renewable energy, and healthcare globally. Major players in the cell therapy technologies market are Thermo Fisher Scientific, Merck, MaxCyte, Lonza Group, Sartorius, Terumo BCT, Fresenius Medical Care AG & Co. KGaA, Avantor Inc., Miltenyi Biotec, STEMCELL Technologies Inc., Beckman Coulter, Danaher, Becton Dickinson and Company, and GE Healthcare. North America was the largest region in the cell therapy technologies market in 2020. Asia Pacific is predicted to record fastest growth over the forecast period. The regions covered in the cell therapy technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell therapy technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cell therapy technologies market is segmented - 1) By Product: Consumables, Equipment, Systems & Software 2) By Cell Type: T-Cells, Stem Cells, Other Cells 3) By Process: Cell Processing, Cell Preservation, Distribution And Handling, Process Monitoring And Quality Control 4) By End-User: Life Science Companies, Research Institutes

Home Health Care And Residential Nursing Care Services Market Definition

The home health care and residential nursing care services market consists of the sales of these services and related goods by entities (organizations, sole traders, and partnerships) that provide home health care and residential nursing care. This industry includes establishments that provide home healthcare services, nursing care facility services, personal services, counselling services, vocational therapies, rest home services, social services, and nutritional services. Home health care is defined as a form of supportive care provided by a professional caregiver in an individual home where the patient is residing. These types of services often include help with daily activities such as dressing and bathing the patient, assistance with daily tasks, companionship, therapy, and rehabilitative services and short-term or long-term disease management at home.

The pyrogen testing market consists of sales of pyrogen testing and related services by entities (organizations, sole traders and partnerships) that provide pyrogen testing to check the presence or absence of pyrogens in all aqueous parenterals. Pyrogen testing determines the presence of bacterial toxins in vaccines, biotechnological products, and drugs, which induces fever in humans. It also determines the presence of microbes and their metabolites in drugs during the manufacturing process. The main types of pyrogen tests are LAL test, in vitro test, and rabbit test. The LAL (Limulus Amebocyte Lysate) test is a test for the determination of bacterial endotoxins, which uses the amebocyte lysate of the Limulus crab. The rabbit pyrogen test is a test in which a small amount of batched test material is injected into a rabbit’s bloodstream, and the body temperature of the rabbit is monitored. The products used for pyrogen tests include assays, kits, and reagents, instruments and related services, and are used in pharmaceutical and biologics, medical devices, and other industries. The global pyrogen testing market is expected to grow from $1.03 billion in 2020 to $1.20 billion in 2021 at a compound annual growth rate (CAGR) of 16.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global pyrogen testing market is expected to reach $1.78 billion in 2025 at a CAGR of 10.4%. The rising investments in research and development in the pharmaceutical and biotechnology industries contributed to the growth of the pyrogen testing market. Pyrogen testing is used by pharmaceutical, biotech, and various drug manufacturing companies for the safe manufacturing and introduction of infection-free products into the market. For instance, in 2019, major players in the pharmaceuticals market Roche, AstraZeneca and Merck have invested heavily in R&D activities. Roche invested around $12 billion which represented 19% of its $63.3 billion in sales. Therefore, high investments in research and development by pharmaceuticals companies drive the pyrogen testing market. Companies are focusing on the evolution of various animal-free pyrogen testing methods such as monocyte activation assay (MAT) to overcome constraints of rabbit pyrogen testing method and LAL test, and to produce a human treatment of animals. MAT provides a high level of prediction of pyrogenic activity and also stimulates fever reaction better than the RPT or BET/LAL. MAT pyrogen testing method is used to detect both endotoxin and non-endotoxin pyrogens, but the LAL test is limited to detect only endotoxin pyrogen. For instance, Merck focused on two MAT systems for the detection of pyrogens namely PyroDetect, PyroMAT. Major players in the pyrogen testing market are Thermo Fisher Scientific, Inc., Merck KGaA, Charles River Laboratories, Inc., Lonza Group, Ellab A/S, Nelson Laboratories Inc., Associates of Cape Cod, Inc., GenScript, BioMerieux, Hyglos GmbH, Sanquin, Wako Chemicals USA, Inc., and Pyrostar. North America was the largest region in the pyrogen testing market in 2020. Asia Pacific is expected to continue to be the fastest growing region in the forecast period. The regions covered in the pyrogen testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pyrogen testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pyrogen testing market is segmented - 1) By Test Type: LAL Test, In Vitro Test, Rabbit Test 2) By Product And Service: Assays, Kits, Reagents, Instruments, Services 3) By Application: Pharmaceutical And Biologics, Medical Devices, Others